SCHEMBL3978064

SCHEMBL3978064

COC(=O)c1oc(OC)c(-c2ccccc2)c1-c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.48
LMNA P02545 2/20 0.45
TSHR P16473 1/20 0.43
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
RAB9A P51151 1/20 0.41
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
TP53 P04637 2/20 0.40
AR P10275 1/20 0.40
CELA1 Q9UNI1 1/20 0.40
THRB P10828 1/20 0.39
GRM6 O15303 1/20 0.39
GRM5 P41594 1/20 0.39
FGFR1 P11362 2/20 0.39
SRC P12931 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL72038 0.88 PTGS1 (0.54) PTGS1LMNATSHRKDM4EALDH1A1
SCHEMBL3976143 0.87 PDE4A (0.41) PTGS1LMNATSHRKDM4EALDH1A1
SCHEMBL3975977 0.82 PTGS1 (0.49) PTGS1LMNATSHRKDM4EALDH1A1
SCHEMBL3974214 0.81 PTGS1 (0.48) PTGS1LMNATSHRKDM4EALDH1A1
SCHEMBL22349646 0.73 KDM4E (0.58) LMNAKDM4EALDH1A1SMN1; SMN2RAB9A
SCHEMBL27448744 0.72 PTGS1 (0.46) PTGS1LMNATSHRKDM4EALDH1A1
SCHEMBL3977063 0.71 LMNA (0.45) PTGS1LMNATSHRALDH1A1SMN1; SMN2
SCHEMBL28383801 0.70 ALDH1A1 (0.57) PTGS1LMNAKDM4EALDH1A1SMN1; SMN2
SCHEMBL2778196 0.70 ALDH1A1 (0.74) LMNATSHRKDM4EALDH1A1SMN1; SMN2
SCHEMBL11227892 0.70 LMNA (0.64) PTGS1LMNATSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 PTGS1 1730/4885LMNA 2180/4885TSHR 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.